Sarcomatoid Bladder Tumor: A Rare Variant of Transitional Cell Carcinoma

Aims: Transitional cell carcinoma (TCC) of the bladder encompasses various tumor variants, with the sarcomatoid subtype being aggressive and of rare incidence. This case report aims to present the clinical characteristics, diagnosis, surgical intervention, and post-operative management of a non-smoking 71-year-old female patient. This patient presented with gross hematuria and was subsequently diagnosed with a sarcomatoid bladder tumor through a series of diagnostic evaluations. The report intends to contribute to the existing literature on this rare tumor variant and shed light on the diagnostic challenges and meticulous surgical and post-operative management in the absence of chemoradiation therapy.

Study Design: This case report presents a single case study of a patient diagnosed with sarcomatoid bladder tumor.

Methodology: The patient was a 71-year-old female with no history of smoking, who presented with gross hematuria. Diagnostic evaluations, including imaging studies and histopathological examinations, were performed to determine the presence of a sarcomatoid bladder tumor. Surgical intervention was conducted to remove the tumor, followed by post-operative management without chemoradiation therapy.

Results: The case report presents the successful diagnosis and management of a sarcomatoid bladder tumor in the described patient. Detailed clinical, histopathological, and imaging findings are provided, showcasing the challenges and treatment decisions in the absence of chemoradiation. Conclusion: This case report underscores the significance of recognizing and managing rare tumor variants like sarcomatoid bladder tumor. It adds to the existing medical literature on this subject and emphasizes the importance of careful diagnostic evaluation and meticulous surgical and post-operative care to achieve favorable outcomes in patients affected by this aggressive variant. Further studies and case reports are warranted to advance our understanding and optimize the management of sarcomatoid bladder tumors.